Toremifene
As of the edition of 20 October 2026, Toremifene is a small molecule: marketed, first approved in 1996 (EU); acts on ESR1 and ESR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Fareston
- First approved
- 14 February 1996 (EU)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Kyowa Kirin; 2 holders in all
- Registered trials
- 29, 7 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Injuries; Bones, joints and muscles; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 9 | 4 | 1 | 2 |
| Phase 3 | 13 | 5 | 1 | 4 |
| Phase 4 | 3 | 1 | 0 | 1 |
| All trials | 29 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Orion Pharma | Applicant | 1996 to now |
| Kyowa Kirin | Acquired holder | 2017 to now |